RIGL Q1 2017 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-28.7% YoY

Gross Profit

-$9M-245.3% margin

Operating Income

-$16M-452.1% margin

Net Income

-$15M-427.3% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

+19.5%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$955,000

Balance Sheet

Total Assets

$101M

Total Liabilities

$17M

Stockholders' Equity

$84M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-28.7%
Gross Profit	-$9M	-$13M	+33.1%
Operating Income	-$16M	-$18M	+7.8%
Net Income	-$15M	-$17M	+12.3%